These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease. Barrera-Chimal J; Gerarduzzi C; Rossignol P; Jaisser F Clin Sci (Lond); 2022 Jun; 136(12):1005-1017. PubMed ID: 35765983 [TBL] [Abstract][Full Text] [Related]
25. SGLT-2 Inhibitors and Nephroprotection in Patients with Diabetic and Non-diabetic Chronic Kidney Disease. Sarafidis P; Pella E; Kanbay M; Papagianni A Curr Med Chem; 2023; 30(18):2039-2060. PubMed ID: 36028970 [TBL] [Abstract][Full Text] [Related]
26. Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials. Gohda T; Murakoshi M Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430228 [TBL] [Abstract][Full Text] [Related]
27. A New Hope on the Horizon for Kidney and Cardiovascular Protection with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Mineralocorticoid Receptor Antagonists in Type 2 Diabetic and Chronic Kidney Disease Patients. Spasovski G; Rroji M; Hristov G; Bushljetikj O; Spahia N; Rambabova Bushletikj I Metab Syndr Relat Disord; 2024 Apr; 22(3):170-178. PubMed ID: 38386800 [TBL] [Abstract][Full Text] [Related]
28. Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease. Yao L; Liang X; Wang P Am J Physiol Endocrinol Metab; 2023 Jun; 324(6):E531-E541. PubMed ID: 37166263 [TBL] [Abstract][Full Text] [Related]
29. The mineralocorticoid receptor in chronic kidney disease. Barrera-Chimal J; Jaisser F; Anders HJ Br J Pharmacol; 2022 Jul; 179(13):3152-3164. PubMed ID: 34786690 [TBL] [Abstract][Full Text] [Related]
30. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. Filippatos G; Anker SD; August P; Coats AJS; Januzzi JL; Mankovsky B; Rossing P; Ruilope LM; Pitt B; Sarafidis P; Teerlink JR; Kapelios CJ; Gebel M; Brinker M; Joseph A; Lage A; Bakris G; Agarwal R Eur Heart J Cardiovasc Pharmacother; 2023 Feb; 9(2):183-191. PubMed ID: 36639130 [TBL] [Abstract][Full Text] [Related]
32. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B; Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733 [TBL] [Abstract][Full Text] [Related]
33. Management of type 2 diabetes in chronic kidney disease. Triozzi JL; Parker Gregg L; Virani SS; Navaneethan SD BMJ Open Diabetes Res Care; 2021 Jul; 9(1):. PubMed ID: 34312158 [TBL] [Abstract][Full Text] [Related]
34. Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk. Stephens JW; Brown KE; Min T Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():32-45. PubMed ID: 32267078 [TBL] [Abstract][Full Text] [Related]
35. The emerging pillars of chronic kidney disease: no longer a bystander in metabolic medicine. Wonnacott A Clin Med (Lond); 2023 May; 23(3):254-258. PubMed ID: 37236791 [TBL] [Abstract][Full Text] [Related]
36. Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. Sarafidis P; Ortiz A; Ferro CJ; Halimi JM; Kreutz R; Mallamaci F; Mancia G; Wanner C; J Hypertens; 2021 Jun; 39(6):1090-1097. PubMed ID: 33443971 [TBL] [Abstract][Full Text] [Related]